All articles tagged with #adcs
Originally Published 2 months ago — by EL PAÍS English
New research presented at the European Society for Medical Oncology Congress highlights the promising potential of antibody-drug conjugates (ADCs) as targeted cancer treatments, especially for breast cancer, showing improved survival rates and earlier intervention possibilities, though challenges like toxicity and patient selection remain.
Originally Published 1 year ago — by Yahoo Finance
Pfizer's recent earnings report showed mixed results, with a beat on earnings per share but a miss on revenue expectations, leading to disappointment on Wall Street. CEO Albert Bourla believes the company's $43 billion acquisition of Seagen, an oncology company specializing in antibody drug conjugates (ADCs), will provide the next big opportunity for growth. The acquisition is seen as a way to fill revenue gaps from patent expirations and provide a potential blockbuster pipeline. Despite investor disappointment, analysts are optimistic about Pfizer's future, especially with Seagen's drug Padcev expected to bring in $3.1 billion this year.
Originally Published 2 years ago — by CNBC
Biotech stocks surged after pharmaceutical company AbbVie announced its plans to acquire cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen specializes in antibody-drug conjugates (ADCs), a promising area in the pharmaceutical industry that directly targets cancer cells while sparing healthy ones. The news also boosted the shares of other biotech companies involved in ADC development, including Sutro Biopharma and Mersana Therapeutics. The deal reflects the growing interest of large biopharma companies in ADCs, following similar acquisitions by Pfizer, Merck, and Daiichi Sankyo.
Originally Published 2 years ago — by Endpoints News
Seagen has partnered with Nurix to develop degrader-antibody conjugates (DAC), combining their expertise in antibody-drug conjugates (ADCs) and protein degradation. Seagen will pay $60 million upfront, with the potential for $3.4 billion in milestones and future royalties for Nurix.
Originally Published 2 years ago — by Endpoints News
Takeda has signed a licensing deal with Innate Pharma to use a panel of antibodies to research and develop antibody-drug conjugates (ADCs) for celiac disease. In exchange for exclusive worldwide rights to whatever ADCs are developed using a selection of Innate’s antibodies, Takeda will give Innate a $5 million upfront payment with the potential for $410 million in milestones, plus royalties on net sales of any product resulting from the license.
Originally Published 2 years ago — by CNBC
Pfizer CEO Albert Bourla said the company's $43 billion acquisition of Seagen will allow it to deliver Seagen's cancer therapy at a scale not seen before. Seagen is a leading developer of medicine called antibody-drug conjugates (ADCs), which are designed to kill cancer cells and spare healthy ones. The acquisition will bulk up Pfizer's cancer treatment portfolio, bringing four approved cancer therapies with combined sales of nearly $2 billion in 2022. Pfizer expects to complete the transaction later this year or in early 2024.